The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Hydroxyzine for generalised anxiety disorder
Open accessAbstract
BACKGROUND: Generalised anxiety disorder (GAD) is a common chronic long-term psychiatric disorder, particularly frequent in primary care. There are several treatment options available, both non-pharmacological (i.e. cognitive behavioral therapy) and pharmacological. Among the pharmacological interventions, antidepressants, buspirone and benzodiazepines (BDZs) have been studied in GAD. Hydroxyzine is an anti-histamine medication which has been used in the treatment of anxiety. OBJECTIVES: 1. To determine the efficacy of hydroxyzine in comparison with placebo or any other active agent in alleviating the acute symptoms of GAD. 2. To review acceptability of treatment with hydroxyzine in comparison with placebo or any other active agent. 3. To investigate the adverse effects of hydroxyzine in comparison with other active agents. SEARCH STRATEGY: The Cochrane Depression, Anxiety and Neurosis Group's controlled trial registers (CCDANCTR-Studies and CCDANCTR-References) were searched on 1 March 2010. The author team ran complementary searches on MEDLINE, CINAHL and PsycINFO and checked reference lists of included studies, previous systematic reviews and major textbooks of anxiety disorders. Personal communication with pharmaceutical companies and experts in the field was also undertaken. SELECTION CRITERIA: Randomised controlled trials allocating patients with GAD to hydroxyzine versus placebo and/or any other anxiolytic agent. DATA COLLECTION AND ANALYSIS: Two authors independently extracted data. Information extracted included study characteristics, participant characteristics, intervention details and outcome measures in terms of efficacy (such as the number of patients who responded to treatment or remitted), acceptability (the number of patients who failed to complete the study) and tolerability (side effect profile). MAIN RESULTS: The search yielded 39 studies. We included five studies in the review with a total of 884 participants. We excluded 31 studies and designated three as awaiting assessment. The data from the included studies provide some evidence that hydroxyzine is more effective than placebo for GAD (odds ratio (OR) 0.30, 95% CI 0.15 to 0.58) and that it is also acceptable/tolerable (OR 1.00, 95% CI 0.63 to 1.58) (OR 1.49, 95% CI 0.92 to 2.40). Compared to other anxiolytic agents (benzodiazepines and buspirone), hydroxyzine was equivalent in terms of efficacy, acceptability and tolerability (hydroxyzine vs chloridiazepoxide: OR 0.75, 95% CI 0.35 to 1.62; hydroxyzine vs buspirone efficacy OR 0.76, 95% CI 0.40 to 1.42). In terms of side effects, hydroxyzine was associated with a higher rate of sleepiness/drowsiness than the active comparators (OR 1.74, 95% CI 0.86 to 3.53). There was, however, a high risk of bias in the included studies. AUTHORS' CONCLUSIONS: The included studies did not report on all the outcomes that were pre-specified in the protocol for this review. Even though more effective than placebo, due to the high risk of bias of the included studies, the small number of studies and the overall small sample size, it is not possible to recommend hydroxyzine as a reliable first-line treatment in GAD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Antidepressants for generalised anxiety disorder (GAD)
Kapczinski, F., dos Santos Souza, J. J., Batista Miralha da Cunha, A. A., & Schmitt, R. R. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003592 · Cited by 162
RetractedCochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Hu, R. J. (2003) · Encyclopedia of the Neurological Sciences · doi:10.1016/b0-12-226870-9/01070-4 · Cited by 9,117
(1976) · Medical Entomology and Zoology · Cited by 8,899
Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R)
Spitzer, R. L., & Williams, J. (1987) · Cited by 1,823
Imputing missing standard deviations in meta-analyses can provide accurate results
Furukawa, T. A., Barbui, C., Cipriani, A., Brambilla, P., & Watanabe, N. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.06.006 · Cited by 1,568
Self-citationStatistics Notes: Detecting skewness from summary information: Table 1
Altman, D. G., & Bland, J. M. (1996) · BMJ · doi:10.1136/bmj.313.7066.1200 · Cited by 1,278
DSM-III-R Generalized Anxiety Disorder in the National Comorbidity Survey
Wittchen, H.-U. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950050015002 · Cited by 967
A consumer's guide to subgroup analyses
Oxman, A. D., & Guyatt, G. H. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-1-78 · Cited by 914
Research works printed but not linked: 44
- Goldberg, 1973, The use of hydroxyzine (Vistaril) in the treatment of anxiety neurosis, Psychosomatics, 14, 38, 10.1016/S0033-3182(73)71372-4 · doi:10.1016/s0033-3182(73)71372-4
- Rickels, 1970, Hydroxyzine and chlordiazepoxide in anxious neurotic outpatients: a collaborative controlled study, Comprehensive Psychiatry, 5, 457, 10.1016/0010-440X(70)90006-4 · doi:10.1016/0010-440x(70)90006-4
- Barranco, 1977, Treatment of anxiety with oral hydroxyzine: an overview, Current Therapeutic Research, 22, 217
- Breslow, 1968, Evaluation of hydroxyzine pamoate concentrate as an ataractic: double-blind crossover study in a neurotic male prison group, Current Therapeutic Research, 10, 421
- Burrell, 1960, Hydroxyzine hydrochloride and chlorpromazine: a clinical trial with a group of "tense" psychiatric patients, Canadian Psychiatric Association Journal, 5, 124, 10.1177/070674376000500212 · doi:10.1177/070674376000500212
- Choussat, 1984, Clinical study of hydroxyzine in somatic and psychic manifestations of anxiety, La Vie Medicale, 26, 1157
- Brabander, 1990, Effect of hydroxyzine on attention and memory, Human Psychopharmacology, 5, 357, 10.1002/hup.470050408 · doi:10.1002/hup.470050408
- Dolan, 1958, Management of emotional disturbances: use of hydroxyzine (Atarax) in general practice, California Medicine, 88, 443
- Ende, 1956, Clinical evaluation of Atarax: a non-barbiturate calming agent, Virginia Medical Monthly, 83, 503
- Farah, 1956, Preliminary study on the use of hydroxyzine in psychosomatic affections, International Records of Medicine and GP Clinics, 1, 379
- Ferreri, 1994, Advantages of hydroxyzine in generalized anxiety disorder : A double-blind controlled versus placebo study, L'Encephale, 20, 785
- Garber, 1958, Management of tension and anxiety states with hydroxyzine hydrochloride, Journal of the Florida Medical Association, 45, 549
- Hantouche, 1995, Example of hydroxyzine with detailed analysis of its anxiolytic effects on the FARD scale, Nervure, 8, 10
- Hantouche, 1999, Interactions between psychotherapy and drug therapy in Generalized Anxiety Disorder, Human Psychopharmacology, 14, S87, 10.1002/(SICI)1099-1077(199908)14:1+<S87::AID-HUP122>3.0.CO;2-F · doi:10.1002/(sici)1099-1077(199908)14:1+<s87::aid-hup122>3.0.co;2-f
- Karakostas, 1990, Anxiolysis as a modifying factor of certain neuropsychiatric parameters in patients with coronary heart disease: a double blind placebo-controlled trial of hydroxyzine hydrochloride, Acta Therapeutica, 14, 381
- Lader, 1999, Anxiolytic effect of hydroxyzine: a double blind trial versus placebo and buspirone, Human Psychopharmacology, 14, S94, 10.1002/(SICI)1099-1077(199908)14:1+<S94::AID-HUP123>3.0.CO;2-K · doi:10.1002/(sici)1099-1077(199908)14:1+<s94::aid-hup123>3.0.co;2-k
- Levis, 1957, Pharmcological study on hydroxyzine, U.C.B. 492; a disubstituted piperazine derivative, Archives Internationals de Pharmacodynamie e de Therapie, 109, 127
- Lipton, 1961, High dosages of hydroxyzine in out-patient treatment of severe neuroses and psychoses, The Pennsylvania Medical Journal, 64, 60
- Pishkin, 1967, Stress: psychophysiological and cognitive indices in an acute double-blind study with hydroxyzine in psychiatric patients, Archives of General Psychiatry, 16, 471, 10.1001/archpsyc.1967.01730220083012 · doi:10.1001/archpsyc.1967.01730220083012
- Reisner, 1967, Hydroxyzine for controlling postpartum anxiety: a double-blind study, Nebraska State Medical Journal, 52, 498
- Rickels, 1966, Compliance and improvement in drug-treated and placebo treated neurotic outpatients, Archives of General Psychiatry, 14, 631, 10.1001/archpsyc.1966.01730120071009 · doi:10.1001/archpsyc.1966.01730120071009
- Rickels, 1971, Prognostic indicators of 4-week clinical improvement with chlordiazepoxide and hydroxyzine in anxious neurotic outpatients, International Pharmacopsychiatry, 6, 249
- Robinson, 1957, Hydroxyzine hydrochloride (Atarax): a new tranquillizer, Southern Medical Journal, 50, 1282, 10.1097/00007611-195710000-00015 · doi:10.1097/00007611-195710000-00015
- Samuelian, 1995, Effects on cognitive functions by two anxiolytic treatments on patients with generalized anxiety disorder, L'Encephale, 21, 147
- Settel, 1957, Observations on the use of hydroxyzine in anxiety-tension states and senile agitation, American Practitioner, 8, 1584
- Shalowitz, 1956, Hydroxyzine: a new therapeutic agent for senile anxiety states; a preliminary report, Geriatrics, 11, 312
- Shalowitz, Evaluation of an ataraxic: hydroxyzine in long term therapy, 1961, 174, 357
- Silver, 1969, Hydroxyzine, amitriptyline and their combination in the treatment of psychoneurotic patients, Current Therapeutic Research 1969, 11, 663
- Smigel JO. Lowe, 1959, Emotional and psychic problems of institutionalized geriatric patients: evaluation of hydroxyzine, Journal of the American Geriatric Society, 7, 61, 10.1111/j.1532-5415.1959.tb00580.x · doi:10.1111/j.1532-5415.1959.tb00580.x
- Weber, 1987, Hydroxyzine, sedation of anxiety and functional symptomatology: a collaborative study, Agressologie, 28, 37
- Clyne, 1968, A comparative trial between two tranquillizers, The Practitioner, 10, 421
- Mock, 1965, A clinical evaluation of hydroxyzine and placebo in anxious psychiatric outpatients, International Journal of Neuropsychiatry, 1, 168
- Rzewuska, 2003, [A multicentre double-blind study investigating the anxiolitic efficacy of diazepam, hydroxyzine and tofisopam in patients with generalized anxiety], Farmakoterapia w Psychiatrii i Neurologii [Pharmacotherapy in Psychiatry and Neurology], 3, 53
- Saint-Laurent, 1977, Doxepin in the treatment of neuroses: a comparative clinical study of doxepin, chlordiazepoxide, hydroxyzine, meprobamate and phenobarbital, Current Therapeutic Research, 22, 316
- Sterlin, 1972, The place of doxepin among the anxiolytic-sedative drugs, Current Therapeutic Research, 14, 195
- American Psychiatric Association, 1980, Diagnostic and statistical manual of mental disorders - DSM-III
- Barranco, 1977, Treatment of anxiety with oral hydroxyzine: an overview, Current Therapeutic Research, 22, 217
- Caycedo, 2001, Generalised anxiety disorder, 187, 10.1002/0470846437.ch10 · doi:10.1002/0470846437.ch10
- Griez, 2001, Anxiety Disorders, 10.1002/0470846437 · doi:10.1002/0470846437
- Papadopoulous, 1990, Anxiolysis as a modifying factor of certain neuropsychiatric parameters in patients with coronary heart diseases, Neurologie Psychiatrie, April, 7
- The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2008
- Shalowitz, 1961, Evaluation of an ataraxic (hydroxyzine) in long-term therapy, International Records in Medicine, 174, 367
- World Health Organization, 1978, The Ninth Revision of the International Classification of Diseases and Related Health Problems (ICD-9)
- World Health Organization, 1992, The Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD-10)
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Hydroxyzine has demonstrated efficacy superior to placebo and similar to benzodiazepines and buspirone in RCTs (Level 1) [594,619,620]; however, clinical experience with this agent in the treatment of GAD remains limited.”
BackgroundBaldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“, 2006), some antipsychotic drugs (quetiapine, trifluoperazine) [I (M)] (Lalonde and Van Lieshout, 2011) and the antihistamine hydroxyzine [I (M)] (Guaiana et al., 2010).”
BackgroundInfluentialBenzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573
Histamine and H1-antihistamines: Celebrating a century of progress
Simons, F. E. R., & Simons, K. J. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.09.005 · Cited by 541
Szuhany, K. L., & Simon, N. M. (2022) · JAMA · doi:10.1001/jama.2022.22744 · Cited by 541
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Singewald, N., Schmuckermair, C., Whittle, N., Holmes, A., & Ressler, K. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.004 · Cited by 390
“However, although the H1 antagonist hydroxyzine has been used in some anxiety therapies (Guaiana et al., 2010), the potential clinical use of histaminergic drugs in particular targeting the H2 receptor for CBT augmentation has not been investigated.”
BackgroundStein, M. B., & Sareen, J. (2015) · New England Journal of Medicine · doi:10.1056/nejmcp1502514 · Cited by 314
(2015) · PubMed · Cited by 229
Strawn, J. R., Geracioti, L., Rajdev, N., Clemenza, K., & Levine, A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1491966 · Cited by 214
“Across studies, hydroxyzine was well-tolerated and there were no statistically significant differences in the number of patients experiencing adverse effects between hydroxyzine treated patients and those receiving placebo [76].”
BackgroundInfluentialAbraha, I., Cherubini, A., Cozzolino, F., De Florio, R., Luchetta, M. L., Rimland, J. M., Folletti, I., Marchesi, M., Germani, A., Orso, M., et al. (2015) · BMJ · doi:10.1136/bmj.h2445 · Cited by 165
Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults
McCloud, T. L., Caddy, C., Jochim, J., Rendell, J. M., Diamond, P. R., Shuttleworth, C., Brett, D., Amit, B. H., McShane, R., Hamadi, L., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011611.pub2 · Cited by 102
Self-citationWithdrawing Benzodiazepines in Patients With Anxiety Disorders
Lader, M., & Kyriacou, A. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-015-0642-5 · Cited by 67
Pharmacotherapy for Anxiety Disorders: From First-Line Options to Treatment Resistance
Melaragno, A. J. (2021) · Focus · doi:10.1176/appi.focus.20200048 · Cited by 50
Comprehensive review of generalized anxiety disorder in primary care in Europe.
Parmentier, H., García-Campayo, J., & Prieto, R. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.770731 · Cited by 37
Pharmacotherapy for Anxiety Disorders.
O’Leary, K. B., & Khan, J. S. (2024) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2024.04.012 · Cited by 22
Antidepressants versus placebo for generalised anxiety disorder (GAD)
Kopcalic, K., Arcaro, J., Pinto, A., Ali, S., Barbui, C., Curatoli, C., Martin, J., & Guaiana, G. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012942.pub2 · Cited by 16
Self-citationGeneralized anxiety disorder: Assessment and treatment
Gerlach, A. L., & Stevens, S. (2014) · The Wiley Handbook of Anxiety Disorders · doi:10.1002/9781118775349.ch48 · Cited by 3
Metadata
- Authors
- Guaiana, G., Barbui, C., & Cipriani, A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2010-12-08
- Volume
- 2010
- Issue
- 12
- Pages
- CD006815-CD006815
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1746481573
- Cited by
- 272
- References
- 37
- FWCI
- 7.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.